BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22428685)

  • 1. Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog.
    Dubey N; Varshney R; Shukla J; Ganeshpurkar A; Hazari PP; Bandopadhaya GP; Mishra AK; Trivedi P
    Drug Deliv; 2012 Apr; 19(3):132-42. PubMed ID: 22428685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and biological evaluation of paclitaxel loaded biodegradable PCL/PEG nanoparticles for the treatment of human neuroendocrine pancreatic tumor in mice.
    Dubey N; Shukla J; Hazari PP; Varshney R; Ganeshpurkar A; Mishra AK; Trivedi P; Bandopadhaya GP
    Hell J Nucl Med; 2012; 15(1):9-15. PubMed ID: 22413106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil.
    Yadav AK; Agarwal A; Rai G; Mishra P; Jain S; Mishra AK; Agrawal H; Agrawal GP
    Drug Deliv; 2010 Nov; 17(8):561-72. PubMed ID: 20738221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation on design of stable etoposide-loaded PEG-PCL micelles: effect of molecular weight of PEG-PCL diblock copolymer on the in vitro and in vivo performance of micelles.
    Ukawala M; Rajyaguru T; Chaudhari K; Manjappa AS; Pimple S; Babbar AK; Mathur R; Mishra AK; Murthy RS
    Drug Deliv; 2012 Apr; 19(3):155-67. PubMed ID: 22364230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cRGD-functionalized reduction-sensitive shell-sheddable biodegradable micelles mediate enhanced doxorubicin delivery to human glioma xenografts in vivo.
    Zhu Y; Zhang J; Meng F; Deng C; Cheng R; Feijen J; Zhong Z
    J Control Release; 2016 Jul; 233():29-38. PubMed ID: 27178807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy.
    Gu G; Xia H; Hu Q; Liu Z; Jiang M; Kang T; Miao D; Tu Y; Pang Z; Song Q; Yao L; Chen H; Gao X; Chen J
    Biomaterials; 2013 Jan; 34(1):196-208. PubMed ID: 23069707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery.
    Xu Z; Gu W; Huang J; Sui H; Zhou Z; Yang Y; Yan Z; Li Y
    Int J Pharm; 2005 Jan; 288(2):361-8. PubMed ID: 15620876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.
    Moreno A; Akcakanat A; Munsell MF; Soni A; Yao JC; Meric-Bernstam F
    Endocr Relat Cancer; 2008 Mar; 15(1):257-66. PubMed ID: 18310292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
    De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
    Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin.
    Yadav AK; Mishra P; Jain S; Mishra P; Mishra AK; Agrawal GP
    J Drug Target; 2008 Jul; 16(6):464-78. PubMed ID: 18604659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles.
    Huo M; Zou A; Yao C; Zhang Y; Zhou J; Wang J; Zhu Q; Li J; Zhang Q
    Biomaterials; 2012 Sep; 33(27):6393-407. PubMed ID: 22704599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo.
    Li H; Yuan D; Sun M; Ping Q
    Drug Deliv; 2016 Nov; 23(9):3562-3572. PubMed ID: 27432585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
    Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
    Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
    Han L; Huang R; Liu S; Huang S; Jiang C
    Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer.
    Shenoy DB; Amiji MM
    Int J Pharm; 2005 Apr; 293(1-2):261-70. PubMed ID: 15778064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.
    Miederer M; Henriksen G; Alke A; Mossbrugger I; Quintanilla-Martinez L; Senekowitsch-Schmidtke R; Essler M
    Clin Cancer Res; 2008 Jun; 14(11):3555-61. PubMed ID: 18519789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) nanoparticles: preparation, characterization, and application in doxorubicin delivery.
    Gou M; Zheng X; Men K; Zhang J; Zheng L; Wang X; Luo F; Zhao Y; Zhao X; Wei Y; Qian Z
    J Phys Chem B; 2009 Oct; 113(39):12928-33. PubMed ID: 19736995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles.
    Zhang Y; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Biomaterials; 2012 Jan; 33(2):679-91. PubMed ID: 22019123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors.
    Jiang X; Sha X; Xin H; Chen L; Gao X; Wang X; Law K; Gu J; Chen Y; Jiang Y; Ren X; Ren Q; Fang X
    Biomaterials; 2011 Dec; 32(35):9457-69. PubMed ID: 21911250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
    Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
    Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.